Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Eligibility | NCT00438100 | NCT00662025 | Patients must have BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00438100', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine Arm', ' Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.', ' Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day was... | {'Clinical Trial ID': 'NCT00662025', 'Intervention': ['INTERVENTION 1: ', ' SUNITINIB+CAPECITABINE', ' Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a star... | c94ad26b-1f5e-4446-a4fe-bb949c5dc561 |
Single | Results | NCT00244881 | 30% of the primary trial participants had an increased level of CECs after 42 days of treatment. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00244881', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cediranib Maleate)', ' Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must ha... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4e31e4f8-a6da-49fc-8bfe-1309674ec2ee | |
Single | Results | NCT00089661 | On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity , whereas those in cohort 2 did not experience any Acute Toxicities. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00089661', 'Intervention': ['INTERVENTION 1: ', ' Denosumab 60 mg Q6M', '[Not Specified]', 'INTERVENTION 2: ', ' Placebo', '[Not Specified]'], 'Eligibility': ['Histologically or cytologically confirmed adenocarcinoma of the breast', ' Subjects with early stage disease who are estrogen recep... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5c00f992-5066-42f2-88d7-566b8b9104b5 | |
Single | Eligibility | NCT01527487 | Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial. | Entailment | [
32,
49
] | [] | {'Clinical Trial ID': 'NCT01527487', 'Intervention': ['INTERVENTION 1: ', ' Eribulin+Cyclophosphamide (ErC)', ' Eribulin (Er): 1.4mg/m^2 (Days 1 and 8 of each treatment cycle) by IV infusion', ' Cyclophosphamide (C): 600 mg/m^2 IV (Day 1 of each treatment cycle) by IV infusion', 'INTERVENTION 2: ', ' Docetaxel+Cycl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4c0ffc50-5cb2-4574-b954-335d142edbe4 | |
Comparison | Adverse Events | NCT00810797 | NCT00828074 | Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial. | Entailment | [
0,
5
] | [
0,
8
] | {'Clinical Trial ID': 'NCT00810797', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Exemestane)', ' Patients receive 25mg oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.', ' exemestane: Given orally', ' laboratory biomarker ana... | {'Clinical Trial ID': 'NCT00828074', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Vinorelbine at 20mg/m^2', ' Vinorelbine at 20mg/m^2 weekly intravenous (I.V.) on days 1, 8, 15 and sorafenib 200 mg given orally (p.o.) twice daily for 28 days', 'INTERVENTION 2: ', ' Phase I: Dose Level 2 - Vinorelbi... | 4e3379b9-f971-4ab6-8846-c395f1162bf2 |
Single | Eligibility | NCT00579826 | Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years. | Contradiction | [
0,
2,
6,
8,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00579826', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, daily for 6 months', ' Placebo: Placebo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9872394c-18b7-4f88-849e-0e2831e6ebf0 | |
Comparison | Eligibility | NCT01771666 | NCT01256567 | Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial. | Contradiction | [
0,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 20... | {'Clinical Trial ID': 'NCT01256567', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Docetaxel Combination', ' Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a... | adf3bb50-ec36-467a-987a-f33c10380c60 |
Single | Adverse Events | NCT01875367 | One patient in the primary trial suffered a cerebral infarction. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01875367', 'Intervention': ['INTERVENTION 1: ', ' Arm A: T-IV + T-SC Vial + T-SC Device', ' Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with si... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2ef37a06-a1ed-47eb-b8f4-2f97f46293d1 | |
Single | Results | NCT00477464 | 59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00477464', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1250 mg and Capecitabine 2000 mg/m^2', ' Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 03cb39e4-1d21-47e5-9b09-ebe508eb2a17 | |
Single | Intervention | NCT00425672 | Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00425672', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.', ' ONTAK: Given IV', ' flow cytometry: Correlative studies', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dca6ba74-441e-482f-b667-6c45800ed8c1 | |
Single | Eligibility | NCT01702571 | Patients with incurable and unresectable Locally Advanced Breast Cancer are eligible for the primary trial. | Entailment | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01702571', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine (All Participants)', ' This cohort (Cohort 1) enrolled all participants with HER2 positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | aeecc244-13a9-4944-858e-27ef49585e90 | |
Comparison | Intervention | NCT01256008 | NCT00300781 | the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01256008', 'Intervention': ['INTERVENTION 1: ', ' Stage 1 Clinical Management', ' The group will receive clinical management treatment only each session.', ' Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview an... | {'Clinical Trial ID': 'NCT00300781', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 240, Prior Trastuzumab', ' Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.', 'INTERV... | 741ca5eb-4737-4a35-a9fd-4235d6552b4f |
Single | Results | NCT01881230 | The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b8e0458c-b834-42b5-b5fd-8791f89b0853 | |
Comparison | Adverse Events | NCT00382018 | NCT03012477 | Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
5
] | {'Clinical Trial ID': 'NCT00382018', 'Intervention': ['INTERVENTION 1: ', ' Arm C1 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)', ' Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTCs at first follow-up (Day 22). Patients would be randomized to maintain current ther... | {'Clinical Trial ID': 'NCT03012477', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin + AZD1775', ' Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 m... | 1a112ed3-8318-493b-8973-10de01794892 |
Comparison | Intervention | NCT00003404 | NCT00711529 | the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00003404', 'Intervention': ['INTERVENTION 1: ', ' Adjuvant Radiotherapy', ' Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.', ' Adjuvant Radiotherapy: Adjuvant radiation therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically proven p... | {'Clinical Trial ID': 'NCT00711529', 'Intervention': ['INTERVENTION 1: ', ' Hypnotherapy', ' Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of sel... | 6044590d-0f89-4a6e-8be7-54ca0c0327d9 |
Single | Eligibility | NCT02429427 | Patients with a platelet count of 50 x 109/l are not eligible for the primary trial | Entailment | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT02429427', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.', ' Celecoxib: Patients will receive 400mg of Celecoxib o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8d3378f7-caaf-4654-b12a-382a0e911eb1 | |
Comparison | Results | NCT01516736 | NCT00733408 | the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01516736', 'Intervention': ['INTERVENTION 1: ', ' LA-EP2006', ' During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemothe... | {'Clinical Trial ID': 'NCT00733408', 'Intervention': ['INTERVENTION 1: ', ' Tx (Chemo, MoAb, and Enzyme Inhibitor)', ' INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 d... | f701473d-e034-4a06-9829-d20cc483162c |
Single | Results | NCT00450866 | In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00450866', 'Intervention': ['INTERVENTION 1: ', ' Epothilone B: Group A', ' Group A: Patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT). Patupilone will be administered as a single intravenous infusion over 20 minute... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3889cecd-aa2d-4f58-857e-11d7209f9cf4 | |
Single | Results | NCT00338286 | No participants of the primary trial had a Progression Free Survival over 1 year. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00338286', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care (SOC)', " Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.", 'INTERVENTION 2: ', ' Epoetin Alfa', ' Participants received SOC plus epoetin alfa 40,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19d0c9de-02ad-4a8e-937b-e9d0f0cc8051 | |
Comparison | Adverse Events | NCT00789581 | NCT02445586 | the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00789581', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.', ' Doxorubicin: 60 mg/m2', ' Cyclophosphamide: 600 mg/m2', ' Ixabepilone (Ixempra): 40 mg/m2', 'IN... | {'Clinical Trial ID': 'NCT02445586', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Docetaxel', ' Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, wh... | cb023dbc-3e99-4c32-a857-7f8d49ef5a96 |
Single | Eligibility | NCT00193180 | A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial. | Entailment | [
0,
6,
8,
16
] | [] | {'Clinical Trial ID': 'NCT00193180', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1d0ce237-70eb-45b4-9c77-f0b70d410387 | |
Comparison | Eligibility | NCT00256243 | NCT00721630 | Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00256243', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (C... | {'Clinical Trial ID': 'NCT00721630', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Lapatinib', ' The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7... | 93290529-38b1-444b-9ac8-fa32b98821c5 |
Single | Eligibility | NCT00436917 | Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA). | Entailment | [
39,
40,
41
] | [] | {'Clinical Trial ID': 'NCT00436917', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid', ' 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of localized breast cancer', ' Stage I-IIIA disease', ' Adequately ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dad5ecc6-afcf-496c-8193-778a100c0318 | |
Single | Eligibility | NCT00976989 | Patients with LVEF greater than or equal to 60% are eligible for the primary trial. | Entailment | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT00976989', 'Intervention': ['INTERVENTION 1: ', ' T+P Concomitant Anthracycline-based Chemotherapy', ' 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d0efe29c-1d76-4129-9cf5-2955564d1370 | |
Comparison | Adverse Events | NCT01048099 | NCT02502864 | the primary trial recorded 2.38% more total adverse events than the secondary trial | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01048099', 'Intervention': ['INTERVENTION 1: ', ' Patients Treated', ' Patients who received study treatment'], 'Eligibility': ['Inclusion Criteria:', ' Part I', ' Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor... | {'Clinical Trial ID': 'NCT02502864', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care + Surveys', ' Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.'], 'Eligibility': ['Inclusion Criteria:', ' Must have histologi... | 63ec91be-7e12-431e-84b0-ca401bfb157b |
Single | Results | NCT00373256 | Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months. | Contradiction | [
0,
1,
2,
3,
4,
5,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00373256', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Paclitaxel', ' Starting sunitinib doses of 25 mg daily. After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fd5af11f-7270-49d5-924a-755ff399c463 | |
Single | Intervention | NCT02186015 | Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02186015', 'Intervention': ['INTERVENTION 1: ', ' Cholecalciferol', ' Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.', 'INTERVENTION 2: ', ' No Cholecalciferol', ' Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no in... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f07e932e-1d79-4e1f-9ac2-ed9e2db1c276 | |
Single | Adverse Events | NCT00924352 | One patient in the primary trial had abnormally low levels of AST, ALT and ANC. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00924352', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Dasatinib', ' Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6a5ee728-7db9-4ec0-b98c-0500e9a6187e | |
Comparison | Intervention | NCT02297412 | NCT02667626 | Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02297412', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Minocycline Hydrochloride)', ' Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': 'NCT02667626', 'Intervention': ['INTERVENTION 1: ', ' SCPR Intervention', ' Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive heal... | a495df61-260d-479c-8d5f-d586f295c672 |
Single | Intervention | NCT01105650 | Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01105650', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: CsA', ' Fludarabine: Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).', ' Cyclophosphamide: Administered intravenously, 60 mg/kg, days -5 and -4.', 'Cyclosporine (CsA): Administered intravenously, 1.5 mg/kg for targ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 917afeec-5152-4424-89e3-7f3ffad6378f | |
Single | Eligibility | NCT01617668 | Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial. | Entailment | [
0,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT01617668', 'Intervention': ['INTERVENTION 1: ', ' LCL161 + Paclitaxel (Gene Expression Signature Positive)', ' Patients randomized to the experimental arm for gene expression signature positive received LCL161 1800 mg once weekly + paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of pa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6 | |
Comparison | Eligibility | NCT02244580 | NCT01901146 | Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial. | Contradiction | [
0,
3
] | [
0,
5,
7
] | {'Clinical Trial ID': 'NCT02244580', 'Intervention': ['INTERVENTION 1: ', ' Luminal A', ' Patients subtyped as Luminal A with DDFS determined 5 years after randomisation', 'INTERVENTION 2: ', ' Combined Subtype', ' Patients subtyped as Luminal B, HER2 positive, triple negative with DDFS determined 5 years after ran... | {'Clinical Trial ID': 'NCT01901146', 'Intervention': ['INTERVENTION 1: ', ' ABP 980', ' Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.', 'INTERVENTI... | f5aa1aa3-7be3-4518-8cc5-df2394e70e96 |
Single | Results | NCT03584009 | Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT03584009', 'Intervention': ['INTERVENTION 1: ', ' Venetoclax + Fulvestrant', ' Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).', 'INTERVENTION 2: ', ' Fulvestrant', ' Part... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45338f7c-5aaa-40fb-8503-7c943e1f3a29 | |
Comparison | Intervention | NCT00429507 | NCT00038467 | Unlike the secondary trial, the primary trial does not administer any medication orally. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00429507', 'Intervention': ['INTERVENTION 1: ', ' Samarium 153-EDTMP + Stem Cell Transplant', ' Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant D... | {'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received ... | 0964be32-f9e7-49ec-ad22-b030d483702a |
Single | Eligibility | NCT01527487 | Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53
] | [] | {'Clinical Trial ID': 'NCT01527487', 'Intervention': ['INTERVENTION 1: ', ' Eribulin+Cyclophosphamide (ErC)', ' Eribulin (Er): 1.4mg/m^2 (Days 1 and 8 of each treatment cycle) by IV infusion', ' Cyclophosphamide (C): 600 mg/m^2 IV (Day 1 of each treatment cycle) by IV infusion', 'INTERVENTION 2: ', ' Docetaxel+Cycl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 73cfc4ea-afc0-465b-a403-c1bd771ded33 | |
Single | Eligibility | NCT00876395 | Patients suffering from Ulcerative colitis are excluded from the primary trial. | Entailment | [
9,
15
] | [] | {'Clinical Trial ID': 'NCT00876395', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Paclitaxel + Trastuzumab', ' Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22', 'INTERVENTION 2: ', ' Placebo + Paclitaxel + Trastuzumab', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 75b67d63-9727-418d-afd5-c0fb867417b5 | |
Single | Adverse Events | NCT01671319 | 1/42 patients in cohort 2 of the primary trial fainted. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01671319', 'Intervention': ['INTERVENTION 1: ', ' Dose Dense TC + Pegfilgrastim', ' Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle', ' docetaxel + cyclophosphamide + pegfilgrastim: docetaxel 75 mg/m2 + c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94cd9451-35a4-4035-a7de-2d385f771607 | |
Single | Adverse Events | NCT00068341 | More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00068341', 'Intervention': ['INTERVENTION 1: ', ' Arm I: HER2+', '(Pre-Op TCH)', 'INTERVENTION 2: ', ' Arm II: HER2+', ' (Pre-Op TC, Post-Op Herceptin)'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed infiltrating adenocarcinoma of the breast', ' Primary breast cancer > 5cm, or skin/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 18310f83-54ca-4530-92f1-7c41419ab69e | |
Single | Adverse Events | NCT00567190 | There was the same number of anemic patinets in both cohorts of the primary trial. | Entailment | [
0,
2,
12,
14
] | [] | {'Clinical Trial ID': 'NCT00567190', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Docetaxel', ' Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milli... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4fa6b99e-0e70-465d-8b24-b728979b3689 | |
Single | Eligibility | NCT00627978 | Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry. | Contradiction | [
18,
19
] | [] | {'Clinical Trial ID': 'NCT00627978', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Participants are treated with Ixabepilone.', ' ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours', 'INTERVENTION 2: ', ' Control', ' No treatment with Ixabepilone'], 'Eligibility': ['Inclusion Criteria', ' Ability to unde... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e0fac0a4-a5ab-4089-8986-f601586506af | |
Single | Eligibility | NCT01847001 | Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01847001', 'Intervention': ['INTERVENTION 1: ', ' Propranolol + Neoadjuvant Chemotherapy', ' Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.', ' Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 85210693-996a-4ab9-92f4-62060571da21 | |
Single | Adverse Events | NCT00148668 | Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00148668', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Herceptin/navelbine', 'INTERVENTION 2: ', ' Arm 2', ' Taxotere/carboplatin/herceptin'], 'Eligibility': ['Inclusion Criteria:', ' Patients with stage II or III breast cancer', ' HER-2 positive tumors', ' Older than 18 years of a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f0fbdbf4-af12-4cde-a5f1-a56cc60658f4 | |
Comparison | Adverse Events | NCT01310231 | NCT00093808 | 1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01310231', 'Intervention': ['INTERVENTION 1: ', ' Metformin', ' Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).', ' Metformin: metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, pla... | {'Clinical Trial ID': 'NCT00093808', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Vinorelbine + Trastuzumab', ' Treatment followed a 21-day cycle. Capecitabine was administered orally twice daily at a dose of 825 mg/m^2 on days 1 to 14, vinorelbine was administered intravenously (IV) at a dose of 25 mg/m^2 o... | 6a37e999-4b7e-4654-b9ac-7776a0720040 |
Comparison | Adverse Events | NCT00423917 | NCT00082641 | the primary trial and the secondary trial both report cases of confusion in all their patient cohorts. | Contradiction | [
0,
5
] | [
0,
7,
8,
15
] | {'Clinical Trial ID': 'NCT00423917', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Bevacizumab', ' Patients receive Fulvestrant 250 mg intramuscularly every 28 days and Bevacizumab 10mg/kg intravenously with a rate-regulating device on days 1 and 15. Loading dose of fulvestrant for the first cycle will consist... | {'Clinical Trial ID': 'NCT00082641', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients wi... | a625ff4b-9c91-4ab8-a78b-df833d15759a |
Single | Adverse Events | NCT00082641 | At least one patient in the primary trial suffered from a life threatening bone fracture. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00082641', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients wi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b25e7c40-a1db-4ae7-9613-0f65ddb4c040 | |
Single | Adverse Events | NCT00856492 | Cohort 1 of the primary trial recorded no deaths and no cases of Anemia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00856492', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G))', ' Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 25f1f3b8-15ed-4339-bf56-1cf1e0c2909f | |
Single | Results | NCT01268150 | The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01268150', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle.'], 'Eligibility': ['Key Inclusion Criteria', ' Females age 18 years or older at ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c0ddffa9-4a88-4ee1-8525-a77e887c3d85 | |
Comparison | Eligibility | NCT00129389 | NCT00304096 | Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial. | Entailment | [
22,
30
] | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53
] | {'Clinical Trial ID': 'NCT00129389', 'Intervention': ['INTERVENTION 1: ', ' Arm A: FAC', ' FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.', 'INTERVENTION 2: ', ' Arm B: FAC-wP', ' FAC X 4 + 8 weekl... | {'Clinical Trial ID': 'NCT00304096', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Received Hormonal Therapy', ' Participants received hormonal therapy', 'INTERVENTION 2: ', ' Stratum 2: Had Not Received Hormonal Therapy', ' Participants had not received hormonal therapy'], 'Eligibility': ['DISEASE CHARACTERIST... | 64ea58e5-e28f-42bc-818e-31bbf347080c |
Single | Intervention | NCT01905592 | the primary trial only defines intervention dosage for cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01905592', 'Intervention': ['INTERVENTION 1: ', " Physician's Choice", ' Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine), until progression or unacceptable toxicity develops.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7a0f4365-9775-4f1d-a1c7-4630b41b43ea | |
Single | Eligibility | NCT01073865 | Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01073865', 'Intervention': ['INTERVENTION 1: ', ' Zoladex 10.8 mg', ' ZOLADEX 10.8 mg (goserelin acetate): one subcutaneous depot injection into interior abdominal wall once every 12 weeks', 'INTERVENTION 2: ', ' Zoladex 3.6 mg', ' ZOLADEX 3.6 mg (goserelin acetate): one subcutaneous depot... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 64dcb690-ef14-4cf2-85e5-670eb0645d7f | |
Single | Results | NCT01566721 | More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01566721', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: SC Herceptin by Needle/Syringe', ' Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by n... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cacd1b1b-510e-421b-9adb-c5715f281794 | |
Single | Adverse Events | NCT02502864 | The maximum number of occurences for an adverse event in the primary trial was 3. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT02502864', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care + Surveys', ' Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.'], 'Eligibility': ['Inclusion Criteria:', ' Must have histologi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c3e5a015-e8b5-4281-828c-deb1f7fc7e3a | |
Single | Results | NCT01401166 | All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01401166', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: SC (SID) Then IV Herceptin', ' Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin was administered via SID, and during Cycles 5 to 8, IV Herceptin ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7926bfa3-cf49-4589-8143-0a0826336b67 | |
Comparison | Intervention | NCT00975676 | NCT00632489 | the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00975676', 'Intervention': ['INTERVENTION 1: ', ' Triptorelin Plus Tamoxifen', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', 'INTERVENTION 2: ', ' Triptorelin Plus Exemestane', ' Determination of estrogen leve... | {'Clinical Trial ID': 'NCT00632489', 'Intervention': ['INTERVENTION 1: ', ' LBH589 With Capecitabine', ' MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and... | 1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b |
Comparison | Adverse Events | NCT00887575 | NCT01610284 | Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00887575', 'Intervention': ['INTERVENTION 1: ', ' Phase II- Sunitinib/Paclitaxel/Carboplatin', ' Systemic Therapy based on maximum tolerated dose (MTD) of the Phase I portion'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years', ' Histologically confirmed invasive ER-... | {'Clinical Trial ID': 'NCT01610284', 'Intervention': ['INTERVENTION 1: ', ' BKM120 100mg + Fulvestrant', ' BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.', 'INTERVENTION 2: ', ' Placebo + Fulvestrant', ' BKM120 matching placebo daily and fulvestrant given until progre... | a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42 |
Comparison | Adverse Events | NCT01269346 | NCT01597193 | Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total number of adverse events. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01269346', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate in Combination With Trastuzumab', ' Eribulin Mesylate: Eribulin mesylate 1.4 mg/m^2 was administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.', ' Trastuzumab 8 mg/kg was ad... | {'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including a... | 36957dd8-fe28-4b70-b651-8f6ea7d1d0e9 |
Single | Adverse Events | NCT01111825 | There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [] | {'Clinical Trial ID': 'NCT01111825', 'Intervention': ['INTERVENTION 1: ', ' Phase 2 Triple -ve', ' Phase 2, Triple - Negative cohort', 'INTERVENTION 2: ', ' Phase 2 HER2+', ' Phase 2, HER2 - Amplified (HER2-Positive) cohort'], 'Eligibility': ['Inclusion Criteria:', ' Phase I HER2-amplified Cohort', ' HER2 overexp... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1aee22c7-96f2-4ea6-909a-48741f87ba07 | |
Single | Intervention | NCT00513695 | paclitaxel is the only drug in the primary trial given by IV. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00513695', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Chemotherapy Before Surgery)', ' Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unac... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d677707e-9ca9-4801-8fcd-7960a9f4f30a | |
Comparison | Intervention | NCT03252145 | NCT00904033 | None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03252145', 'Intervention': ['INTERVENTION 1: ', ' Manual Lymph Drainage', ' Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb vol... | {'Clinical Trial ID': 'NCT00904033', 'Intervention': ['INTERVENTION 1: ', ' No Exercise', ' Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week', 'INTERVENTION 2: ', ' Exercise', ' Exercise Arm: Exercise consisting of progressive walking and resistance band training', ' Calcitriol+ Exercise Arm: ... | 5335a9c9-bae1-42e9-9428-eb0eded62d7f |
Single | Results | NCT01307891 | Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01307891', 'Intervention': ['INTERVENTION 1: ', ' Abraxane + Tigatuzumab', ' Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every oth... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e6c0f7af-b549-4aad-8f3c-15f367a04a50 | |
Single | Adverse Events | NCT00929240 | There are no cases of Febrile bone marrow aplasia in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00929240', 'Intervention': ['INTERVENTION 1: ', ' Maintenance Phase: Bevacizumab', " During the Initial Phase all participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1fc3aeac-3bc0-4a47-8222-ea267a822804 | |
Single | Intervention | NCT00320411 | the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00320411', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Monotherapy', ' Lapatinib: 1500 mg (six 250 mg tablets) orally once daily'], 'Eligibility': ['Inclusion Criteria:', ' A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9e664bcb-38cc-4ca6-9738-28d96248b7f2 | |
Single | Adverse Events | NCT02924883 | In the primary trial, all cases of Enteritis, Vertigo and Anaemia occurred in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT02924883', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine + Placebo', ' Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or stu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1b8403ac-7eb3-41cb-8b7e-a89af3492805 | |
Single | Eligibility | NCT03004534 | Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial. | Entailment | [
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT03004534', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Molecular Assessment', ' Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.', ' darolutamide: Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.'], 'Eligibil... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ad853675-40ed-4a65-a401-d09ac3153570 | |
Single | Results | NCT00493636 | Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00493636', 'Intervention': ['INTERVENTION 1: ', ' A (Sorafenib + Gemcitabine or Capecitabine)', ' Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Cape... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b43bee02-cc3f-4dc8-b13f-8a93de5dc422 | |
Single | Results | NCT00050011 | the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00050011', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Upfront', ' Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 62258901-8207-413d-913f-a04682635add | |
Single | Results | NCT02657889 | Both the primary trial cohorts reported identical results. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02657889', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Niraparib 200mg + Pembrolizumab', ' Niraparib 200 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Phase 1: Niraparib 300mg + Pembrolizumab', ' Niraparib 300 mg/day ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d23aee47-e80f-42fe-b095-9cd81f9e0ed3 | |
Single | Results | NCT00524303 | The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00524303', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-we... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d23eb56e-c232-4754-94aa-903bc174cb35 | |
Single | Eligibility | NCT00562718 | Patients with breast implants are always excluded from the primary trial. | Contradiction | [
6
] | [] | {'Clinical Trial ID': 'NCT00562718', 'Intervention': ['INTERVENTION 1: ', ' Surgery and Chemotherapy', ' Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.', ' capecitabine', ' adjuvant ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1c0dcd29-4a04-4b78-abbf-b047d4c29597 | |
Single | Adverse Events | NCT01298193 | More than 20% of patients in cohort 1 of the primary trial experienced adverse events. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01298193', 'Intervention': ['INTERVENTION 1: ', ' Observational Phase (First Cycle):', ' Observational phase (first cycle):', ' Day 0 (Dexamethasone 8mg) Day 1 (5-hydroxytryptamine 3 [5-HT3] antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg).', ' C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b1a17048-dfe8-4173-ae80-6ec273244848 | |
Single | Results | NCT01808573 | the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01808573', 'Intervention': ['INTERVENTION 1: ', ' Neratinib Plus Capecitabine', ' neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 33652443-0bb4-493e-adfe-f5032b96b13d | |
Single | Eligibility | NCT00228943 | Clinically anxious patients are not able to participate in the primary trial. | Contradiction | [
8,
9
] | [] | {'Clinical Trial ID': 'NCT00228943', 'Intervention': ['INTERVENTION 1: ', ' Full Strength Acute Tryptophan Depletion', '[Not Specified]', 'INTERVENTION 2: ', ' Half-Strength Tryptophan Depletion - Control', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' At least 18 years of age', ' Willing and able to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 74dba58a-8f5d-478b-a886-0e9758847fe3 | |
Single | Results | NCT02131064 | less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02131064', 'Intervention': ['INTERVENTION 1: ', ' TCH + P', ' Participants received pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion, trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion, ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5344044c-127d-4a39-80dc-277538b5ad33 | |
Single | Adverse Events | NCT00820872 | Hyperglycemia was the most common adverse event in cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00820872', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ed43519d-9954-4e0f-9d42-39a3ed81e4a5 | |
Single | Adverse Events | NCT00929240 | There are no cases of Febrile neutropenia in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00929240', 'Intervention': ['INTERVENTION 1: ', ' Maintenance Phase: Bevacizumab', " During the Initial Phase all participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8d2fde27-a5e8-40ee-a35d-3d4697198a4e | |
Single | Results | NCT00676663 | The the primary trial placebo group performed worse than the test group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00676663', 'Intervention': ['INTERVENTION 1: ', ' Exemestane 25 mg + Placebo', ' Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fc0da76b-e5b5-44e3-abaf-6231fff493c3 | |
Single | Results | NCT00119262 | cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00119262', 'Intervention': ['INTERVENTION 1: ', ' Arm A (ddBAC > BT > B)', ' Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab', 'INTERVENTION 2: ', ' Arm B (ddAC > BT > B)', ' Dose dense doxorubicin and cyclophosphami... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1a32e1c1-31b1-40e5-bbb6-84041ef796fe | |
Single | Adverse Events | NCT02291913 | One patient in the primary trial suffered from an inflammation of the esophagus. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT02291913', 'Intervention': ['INTERVENTION 1: ', ' Everolimus', ' Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9a31db67-e28a-4114-a308-e899f9c22813 | |
Comparison | Eligibility | NCT00996632 | NCT01644890 | Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial. | Entailment | [
0,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00996632', 'Intervention': ['INTERVENTION 1: ', ' Ultrasonic', ' Patients were operated using an ultrasonic knife (Ultracision Ethicon TM)', 'INTERVENTION 2: ', ' Conventional', ' Patients were operated by a conventional diatherm knife'], 'Eligibility': ['Inclusion Criteria:', ' Operable ... | {'Clinical Trial ID': 'NCT01644890', 'Intervention': ['INTERVENTION 1: ', ' NK105', ' received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', 'INTERVENTION 2: ', ' Paclitaxel', ' received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' Written inf... | f948a2d1-2e22-47c8-9345-0eb68569bd3f |
Single | Eligibility | NCT00479674 | Patients that have previously been trated with bevacizumab are not eligible for the primary trial, unless they have also received carboplatin 2 weeks prior to study entry. | Contradiction | [
22,
24
] | [] | {'Clinical Trial ID': 'NCT00479674', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Carboplatin, Bevacizumab', ' Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15', ' Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e3265040-8316-4f62-969c-27af396ba18c | |
Single | Eligibility | NCT00656019 | Candidates with hyperparathyroidism are automatically excluded from the primary trial. | Entailment | [
6,
7
] | [] | {'Clinical Trial ID': 'NCT00656019', 'Intervention': ['INTERVENTION 1: ', ' Normal Vitamin D Levels', ' No additional Vitamin D administered', 'INTERVENTION 2: ', ' Low-normal Vitamin D Levels', ' 2000 IU dose of Vitamin D per day administered orally'], 'Eligibility': ['INCLUSION CRITERIA:', ' Undergoing core need... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6c25e195-47cd-48af-bb51-5b5c44772baa | |
Single | Results | NCT00171340 | the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00171340', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 4 mg Upfront', ' Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 382747d3-69df-41be-a771-4218407ce5d3 | |
Single | Results | NCT00376688 | Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00376688', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Temsirolimus)', ' Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' Temsirolimus: Given IV'], 'Eligibility':... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d05ec90a-f267-44be-aaa6-3be960a0d50c | |
Comparison | Adverse Events | NCT02301988 | NCT00728949 | The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains . | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT02301988', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib + Paclitaxel', ' Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).', 'INTERVENTION 2: ', ' Placeb... | {'Clinical Trial ID': 'NCT00728949', 'Intervention': ['INTERVENTION 1: ', ' IMC-A12 (Cixutumumab) + Antiestrogen Therapy', ' Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory... | 37301690-9b68-48de-b280-6307e632043e |
Comparison | Eligibility | NCT00356148 | NCT01856543 | Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00356148', 'Intervention': ['INTERVENTION 1: ', ' Prophylaxis Group', ' patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', 'INTERVENTION 2: ', ' No Prophylaxis Group', ' Patients who are BMI over 25 and not receive antibiotic prophylaxis'], 'Eligibility': ['Inclu... | {'Clinical Trial ID': 'NCT01856543', 'Intervention': ['INTERVENTION 1: ', ' Eucerin', ' Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve applicati... | b61e798c-d38f-4c72-91bb-4d3e28b6184c |
Comparison | Eligibility | NCT00201760 | NCT00127933 | Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial. | Entailment | [
0,
1
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00201760', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 Gemcitabine/Cisplatin/Trastuzumab', ' Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not adm... | {'Clinical Trial ID': 'NCT00127933', 'Intervention': ['INTERVENTION 1: ', ' HER2-Neu Negative', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week t... | 3ca27248-0728-4b10-b940-6e2603acef30 |
Comparison | Eligibility | NCT00248170 | NCT01299038 | Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial. | Entailment | [
0,
1
] | [
6,
10
] | {'Clinical Trial ID': 'NCT00248170', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg by mouth (p.o.) once daily', 'INTERVENTION 2: ', ' Anastrozole', ' 1 mg p.o. once daily'], 'Eligibility': ['Inclusion Criteria:', ' Recent primary surgery for breast cancer', ' Early stage breast cancer', ' Postmenop... | {'Clinical Trial ID': 'NCT01299038', 'Intervention': ['INTERVENTION 1: ', ' Rosuvastatin 20mg', ' Rosuvastatin 20mg taken orally once a day for 4 weeks', ' rosuvastatin: Taken orally once a day for 4 weeks', 'INTERVENTION 2: ', ' Rosuvastatin 40mg', ' Rosuvastatin 40mg taken orally once a day for 4 weeks', ' rosu... | c2da6504-96a1-4669-b609-16731a5330d3 |
Single | Adverse Events | NCT01262027 | Less than 5% of patients in the primary trial suffered an adverse event. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01262027', 'Intervention': ['INTERVENTION 1: ', ' Dovitinib', ' Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Patients have histological confirmati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 646959e4-25d0-4eb1-b7b0-2d7b1e02e132 | |
Comparison | Intervention | NCT01293032 | NCT00849472 | None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01293032', 'Intervention': ['INTERVENTION 1: ', ' Group 2 (RS 11-25)', ' Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy, or treatment Arm 2, neoadjuvant chemotherapy.'], 'Eligibility': ['Incl... | {'Clinical Trial ID': 'NCT00849472', 'Intervention': ['INTERVENTION 1: ', ' AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib', ' Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was... | 0e6eebe9-46c2-4fa5-b9ed-e0997044960b |
Single | Results | NCT00950742 | 100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities. | Entailment | [
0,
1,
2,
3,
10,
11,
12,
13,
8,
15
] | [] | {'Clinical Trial ID': 'NCT00950742', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 20mg + Herceptin', ' Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a781374c-99e1-47ee-a266-bff9267c2ed1 | |
Single | Results | NCT01151046 | The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01151046', 'Intervention': ['INTERVENTION 1: ', ' MM-121 + Exemestane', ' MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week, plus exemestane (25 mg) administered orally once per day', 'INTERVENTION 2: ', ' Placeb... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9aea5a84-bced-4441-b8b8-154c307f5a03 | |
Single | Adverse Events | NCT00917735 | One patient in cohort 2 of the primary trial died in a motorcycle crash. | Contradiction | [
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00917735', 'Intervention': ['INTERVENTION 1: ', ' Green Tea Extract', ' Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg cat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | deb77d34-76a5-4e6e-bc9d-176cc30eca07 | |
Single | Adverse Events | NCT00068341 | More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00068341', 'Intervention': ['INTERVENTION 1: ', ' Arm I: HER2+', '(Pre-Op TCH)', 'INTERVENTION 2: ', ' Arm II: HER2+', ' (Pre-Op TC, Post-Op Herceptin)'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed infiltrating adenocarcinoma of the breast', ' Primary breast cancer > 5cm, or skin/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bfe97430-fcec-4c4a-9621-51f6ec05d8d3 | |
Single | Results | NCT01421017 | the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01421017', 'Intervention': ['INTERVENTION 1: ', ' IMQ+RT', ' This arm has been closed as of 6/4/2014.', ' Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)', ' Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnigh... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 568beebd-b350-4ba1-b8fc-c43f4d6ed517 | |
Single | Results | NCT00076024 | The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00076024', 'Intervention': ['INTERVENTION 1: ', ' Axitinib + Docetaxel (Phase 2, Double-blind)', ' Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment wa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6bcc18b7-b063-49a1-8ab7-773636c02f1d | |
Single | Results | NCT01519700 | There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01519700', 'Intervention': ['INTERVENTION 1: ', ' EP2006 + EP2006 & Neupogen', ' All subjects randomized to receive either EP2006 in Cycle 1', 'INTERVENTION 2: ', ' Neupogen + Neupogen & EP2006', ' All subjects randomized to receive Neupogen in Cycle 1'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dfa2ecee-96cf-4551-875e-aedd8aac5df9 | |
Comparison | Adverse Events | NCT00190671 | NCT00455533 | In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia. | Entailment | [
0,
5,
14,
19
] | [
0,
3,
12,
15
] | {'Clinical Trial ID': 'NCT00190671', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed 600mg/m2', ' Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles', 'INTERVENTION 2: ', ' Pemetrexed 1800mg/m2', ' Pemetrexed: 1800 mg/m2, intravenous, ev... | {'Clinical Trial ID': 'NCT00455533', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)', 'INTERVENTION 2: ', ' Paclitaxel', ' paclitaxel 80 mg/m^2 administered IV every week for 12 weeks'], 'Eligibility': ... | 81c85a29-d449-4f79-a3b3-682ba5f288ca |
Single | Intervention | NCT00338728 | Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00338728', 'Intervention': ['INTERVENTION 1: ', ' Letrozole and Imatinib Mesylate', ' Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women able to comply with... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9c48c5d6-83fd-42cc-aacc-2e888099bcdb | |
Single | Eligibility | NCT00293540 | Males are not eligible for the primary trial. | Entailment | [
0,
1,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT00293540', 'Intervention': ['INTERVENTION 1: ', ' A Mid-luteal Surgery', '[Not Specified]', 'INTERVENTION 2: ', ' B Mid-follicular Surgery', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Estrogen receptor or progesterone receptor positive breast cancer', ' Premenopausal with... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79a3bb0d-315f-4c39-8786-2aa98e2e3f6f | |
Single | Eligibility | NCT00503750 | All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00503750', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab and Abraxane Followed Trastuzumab and Vinorelbine', ' Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cea17554-6736-4b52-b76c-b3c5dc9ecb77 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.